Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC

ACS Applied Electronic Materials Pub Date : 2023-09-01 DOI:10.1016/j.clcc.2023.03.003

Chih-Wen Chen , Tao-Shen Ou , Wei-Shone Chen , Jeng-Kai Jiang , Shung-Haur Yang , Huann-Sheng Wang , Shih-Ching Chang , Yuan-Tzu Lan , Chun-Chi Lin , Hung-Hsin Lin , Sheng-Chieh Huang , Hou-Hsuan Cheng , Yi-Wen Yang , Yu-Zu Lin , Yee Chao , Ling-Wei Wang , Hao-Wei Teng

{"title":"Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability","authors":"Chih-Wen Chen , Tao-Shen Ou , Wei-Shone Chen , Jeng-Kai Jiang , Shung-Haur Yang , Huann-Sheng Wang , Shih-Ching Chang , Yuan-Tzu Lan , Chun-Chi Lin , Hung-Hsin Lin , Sheng-Chieh Huang , Hou-Hsuan Cheng , Yi-Wen Yang , Yu-Zu Lin , Yee Chao , Ling-Wei Wang , Hao-Wei Teng","doi":"10.1016/j.clcc.2023.03.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Colorectal brain metastases (CBMs) are rare with poor prognosis. There is still no standard systemic treatment for multiple or unresectable CBM. our study aimed to explore the impact of anti-VEGF therapy on overall survival, brain-specific disease control, and neurologic symptom burden in patients with CBM<em>.</em></p></div><div><h3>Methods</h3><p>A total of 65 patients with CBM under treatment were retrospectively enrolled and divided into anti-VEGF based systemic therapy or non–anti-VEGF based therapy. A total of 25 patients who received at least 3 cycles of anti-VEGF agent and 40 patients without anti-VEGF therapy were analyzed by endpoints of overall survival (OS), progression-free survival (PFS), intracranial PFS (iPFS) and neurogenic event-free survival (nEFS)<strong><em>.</em></strong> Gene expression in paired primary metastatic colorectal cancer (mCRC), liver, lung and brain metastasis from NCBI data was analyzed using top Gene Ontology (GO) and cBioPortal.</p></div><div><h3>Results</h3><p>Patients who treated with anti-VEGF therapy had significantly longer OS (19.5 vs. 5.5 months, <em>P</em> = .009), iPFS (14.6 vs. 4.1 months, <em>P</em> < .001) and nEFS (17.6 vs. 4.4 months, <em>P</em> < .001). Patients who received anti-VEGF therapy beyond any disease progression presented with superior OS (19.7 vs. 9.4 months, <em>P</em> = .039). Top GO and cBioPortal analysis revealed a stronger molecular function of angiogenesis in intracranial metastasis.</p></div><div><h3>Conclusions</h3><p>Anti-VEGF based systemic therapy showed favorable efficacy that was reflected in longer overall survival, iPFS and NEFS in patients with CBM.</p></div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1533002823000348","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Colorectal brain metastases (CBMs) are rare with poor prognosis. There is still no standard systemic treatment for multiple or unresectable CBM. our study aimed to explore the impact of anti-VEGF therapy on overall survival, brain-specific disease control, and neurologic symptom burden in patients with CBM.

Methods

A total of 65 patients with CBM under treatment were retrospectively enrolled and divided into anti-VEGF based systemic therapy or non–anti-VEGF based therapy. A total of 25 patients who received at least 3 cycles of anti-VEGF agent and 40 patients without anti-VEGF therapy were analyzed by endpoints of overall survival (OS), progression-free survival (PFS), intracranial PFS (iPFS) and neurogenic event-free survival (nEFS). Gene expression in paired primary metastatic colorectal cancer (mCRC), liver, lung and brain metastasis from NCBI data was analyzed using top Gene Ontology (GO) and cBioPortal.

Results

Patients who treated with anti-VEGF therapy had significantly longer OS (19.5 vs. 5.5 months, P = .009), iPFS (14.6 vs. 4.1 months, P < .001) and nEFS (17.6 vs. 4.4 months, P < .001). Patients who received anti-VEGF therapy beyond any disease progression presented with superior OS (19.7 vs. 9.4 months, P = .039). Top GO and cBioPortal analysis revealed a stronger molecular function of angiogenesis in intracranial metastasis.

Conclusions

Anti-VEGF based systemic therapy showed favorable efficacy that was reflected in longer overall survival, iPFS and NEFS in patients with CBM.

查看原文本刊更多论文

抗VEGF治疗可能通过保护大肠癌脑转移患者免受神经功能障碍的影响来延长患者的生存期

背景结直肠癌脑转移瘤（CBMs）是罕见的，预后不良。目前还没有针对多发性或不可切除煤层气的标准全身治疗方法。我们的研究旨在探讨抗VEGF治疗对CBM患者的总生存率、脑特异性疾病控制和神经症状负担的影响。通过总生存期（OS）、无进展生存期（PFS）、颅内PFS（iPFS）和神经源性无事件生存期（nFS）的终点，对总共25名接受了至少3个周期的抗VEGF药物治疗的患者和40名未接受抗VEGF治疗的患者进行了分析。使用顶级基因本体论（GO）和cBioPortal分析NCBI数据中成对原发转移性癌症（mCRC）、肝、肺和脑转移的基因表达。结果接受抗VEGF治疗的患者OS显著延长（19.5个月vs.5.5个月，P=.009），iPFS（14.6个月对4.1个月，P<；.001）和nFS（17.6个月和4.4个月，P<；.001）。在任何疾病进展之后接受抗VEGF治疗的患者表现出优越的OS（19.7个月比9.4个月，P=.039）。Top GO和cBioPortal分析显示，颅内转移中血管生成的分子功能更强。结论以抗VEGF为基础的系统治疗显示出良好的疗效，反映在CBM患者的总生存期更长、iPFS和NEFS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Electronic Materials Multiple-

CiteScore

7.20

自引率

4.30%

发文量

567